AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00775671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: Nebivolol 5 mg by mouth daily for 12 weeks.
Study NCT01878773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Quality Volume CT Scan; MRI Scan
Description: Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.~--------------------------------------------------------------------------------
Study NCT00775671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol ER 100mg by mouth daily for 12 weeks.
Study NCT03552445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus-diphtheria (Td) and PCV13
Description: 154 concomitant Td-PCV13 recipients: one dose of each vaccine administered on Day 0
Study NCT03552445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13 alone
Description: 154 PCV13 recipients: one vaccine injection administered on Day 0
Study NCT03552445 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Td alone
Description: 437 Td recipients: one vaccine injection administered on Day 0
Study NCT02068456 — intervention group
Intervention type: DRUG
Intervention: Roflumilast
Study NCT04473833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Transvaginal Ultrasonography
Description: Participants will undergo transvaginal ultrasonography (TVS) to detect ovarian cancer as part of the Kentucky Ovarian Cancer Screening Program. Those with normal findings will repeat the TVS in one year. Those with abnormal results will repeat the screening in 4-6 weeks.
Study NCT04073368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1957
Description: Amino acids, food study
Study NCT02769741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cashews followed by Control
Description: Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
Study NCT02769741 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control followed by Cashews
Description: Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery
Description: The first stage of GMI includes laterality reconstruction. Patients will view and determine if the various images of body parts to image portrays the right or left side. The second stage targets activation of the primary motor cortex by imagine moving the involved body part. The final stage involves that the patient watches the unaffected body part moving in a mirror to trick the brain into thinking the affected body part is actually moving in a pain-free way. This will be applied for 6 weeks.
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Rehabilitation
Description: Shoulder, elbow and wrist AROM exercises. Elbow flexion and extension, and wrist flexion and extension stretching exercises. Elbow and wrist strengthening exercises. Grip strengthening exercises. This will be applied for 6 weeks.
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Program
Description: Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
Study NCT04073368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1125
Description: Amino acids, food study
Study NCT00307593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Infliximab
Study NCT00307593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab
Study NCT01829035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Transarterial Chemoembolization (cTACE)
Description: Concurrent use of the following material/drug is defined as cTACE in this trial.~* Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil~* Anti-tumor drug:~  1. Unapproved drug/embolization material from each regulatory agency should not be used.~ 2. To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed
Study NCT00382096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vildagliptin
Study NCT04073368 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amino acids, food study
Study NCT04245462 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Cross-sectional
Study NCT00900601 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthrodesis to the sacroiliac joint and symphysis
Description: Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.~To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery.
Study NCT01825603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADH-1
Description: Given IV
Study NCT01825603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01825603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01825603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03282565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training with Brace
Description: A brace will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
Study NCT03282565 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: A brace will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
Study NCT02269735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2640
Description: MK-2640 intravenous infusion administered to participant in a fasted state
Study NCT02269735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin (RHI)
Description: RHI 100 units/mL intravenous infusion to maintain target glycemic level
Study NCT02269735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextrose
Description: Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
Study NCT03282565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Resistance Training with Elastic Band
Description: An elastic band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
Study NCT00905216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heparin sodium - Bergamo
Description: 5.000 UI/mL
Study NCT00905216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium - APP
Description: 5.000 USP
Study NCT00359918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fibrinolysis
Description: Primary PCI
Study NCT00359918 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary PCI
Description: Primary PCI
Study NCT01770652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Oral iron chelator
Study NCT02298985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3 g/day (3 capsules/day) for 6 months
Study NCT02298985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: 3 g/day (3 capsules/day) for 6 months
Study NCT02298985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 3 g/day (3 capsules/day) for 6 months
Study NCT02298985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3 g/day (3 capsules/day) for 6 months
Study NCT04121988 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: 1 mm slice thickness with deep learning based reconstruction algorithm applied to the following sequences:~* Coronal T2 weighted imaging~* Dynamic contrast enhanced T1 weighted imaging~* Coronal contrast enhanced T1 weighted imaging
Study NCT01288027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alglucosidase Alfa
Description: Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
Study NCT00795925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propiverine hydrochloride
Description: coated tablets containing 5 mg~consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d.
Study NCT04134702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture and ear acupuncture using indwelling fixed needles, that will remained in situ several days after surgery until the patients will experience pain
Study NCT00700570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 5mg/kg iv on day 1 of each 2 week cycle.
Study NCT00700570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
Study NCT00700570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85mg/m2 iv on day 1 of each 2 week cycle
Study NCT02441400 — intervention group
Intervention type: DEVICE
Intervention: EndoStim LES Stimulation System
Study NCT04362644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET/CT using PET ligands [F-18]FDG and [F-18]DPA-714
Description: Study participants will undergo PET/CT with the glucose analogue \[F-18\]FDG and the translocator protein (TSPO) ligand \[F-18\]DPA-714 in two separate imaging sessions.
Study NCT04070040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.
Study NCT00090064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine HCl
Description: 125 mg of midomafetamine HCl followed by a supplemental half-dose of 62.5 mg of midomafetamine HCl
Study NCT01262209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable CCTV
Description: This is a small handheld mini screen intended to improve reading.
Study NCT01262209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescopes, telemicroscopes and microscopes
Description: These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
Study NCT00090064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo pill
Description: 125 mg followed by a supplemental half-dose of 62.5 mg
Study NCT00090064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Non-directive therapy provided by a team of two co-therapists
Study NCT00090064 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Non-directive therapy provided by a team of two co-therapists
Study NCT03829501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044
Description: A human anti-ICOS monoclonal antibody
Study NCT03829501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KY1044 and atezolizumab
Description: A human anti-ICOS monoclonal antibody in combination with anti-PD-L1 monoclonal antibody (atezolizumab)
Study NCT01262209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorptive filters
Description: These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
Study NCT01013298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video-guided PCT
Description: extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
Study NCT02360111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00089856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy with allogeneic prostate vaccine
Description: Immunotherapy with allogeneic prostate vaccine
Study NCT00089856 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (Taxotere and prednisone)
Description: Chemotherapy (Taxotere and prednisone)
Study NCT03507062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.9% saline administration
Description: Each patient will receive 0.9%saline based on attending physician decision
Study NCT03507062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ringer's lactate administration
Description: Each patient will receive Ringer's lactate based on attending physician decision
Study NCT03507062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmalyte-like solution administration
Description: Each patient will receive Plasmalyte-like solution based on attending physician decision
Study NCT00382096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT00382096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin + Metformin
Study NCT03849144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog activity
Description: Visiting therapy dogs and their owners, evaluated and registered as therapy dog teams with Pet Partners will be spread around a large room on the Aetna campus. Employees will arrive at scheduled times to visit with the dogs for 15 minutes, talking to the dogs and owners and petting the dogs
Study NCT03849144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low impact exercise
Description: The low impact exercise will consist of stretching exercises conducted by a member of Aetna's wellness team in the same room for 15 minutes.
Study NCT02615275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectric Impedance Analysis
Description: Undergo BIA with seca mBCA
Study NCT02615275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT03819426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Intensity Exercise Intervention
Description: Those in the walking intervention will be instructed to take walks below a brisk pace (low intensity) to improve mood
Study NCT03819426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Intervention
Description: Instructed in high intensity interval training techniques and will be provided videos to follow for implementation of intervention at home that will include short bursts of high energy
Study NCT03600298 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Simulation
Description: Intervention phase: Study participants will be subjected to on-site simulation training focusing on communication, including CRM and non-technical skills in the PICU setting.
Study NCT02269735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
Study NCT01356979 — intervention group
Intervention type: PROCEDURE
Intervention: Medical thoracoscopy
Description: Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
Study NCT02269735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
Study NCT03590834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Center-based Intervention
Description: 1. Center nutrition and physical activity policy modification to increase fruit and vegetable servings and more physical activity throughout the day~2. Staff training and technical assistance~3. Health education on healthy habits (diet, physical activity, sleep, screen time) using the Sesame Workshop Healthy Habits for Life (HHL) resource kit~4. Health contests~5. Gross motor and physical activity program~6. Miranos! activity cards based on children storybooks
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Program
Description: Proprioception exercises for the elbow. Scapulothoracic strengthening exercises. This will be applied for 6 weeks.
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Application
Description: Cold application around the elbow joint for 15 minutes in every session.
Study NCT03969277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cold Application
Description: Cold application around the elbow joint for 15 minutes in every session.
Study NCT00202397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: capsule-shaped 50 mg tablets bid for 8 weeks
Study NCT00202397 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule-shaped tablet bid for 8 weeks
Study NCT01068652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
Study NCT01068652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
Study NCT01068652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: biphasic insulin aspart 30
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
Study NCT01068652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 1000-2000 mg/day in combination with insulin treatment
Study NCT03491306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK
Description: PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high bio compatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
Study NCT02615275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT02615275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02615275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02615275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT01543230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
Study NCT03208179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
Study NCT03208179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulphadoxine-pyrimethamine
Description: Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
Study NCT03208179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine plus azithromycin
Description: Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)